Analysts Predict FHLC Will Hit $78
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2025
0mins
Source: NASDAQ.COM
ETF Performance Overview: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $78.46, indicating a potential upside of 12% from its current trading price of $70.06.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as MoonLake Immunotherapeutics (MLTX), Prestige Consumer Healthcare Inc (PBH), and AtriCure Inc (ATRC), show significant upside potential based on analyst target prices, with MLTX expected to rise by 77.88%, PBH by 35.21%, and ATRC by 34.73%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent developments in the companies or industry.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of the analysts' targets and to understand the implications of the current market conditions on these price predictions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBH
Wall Street analysts forecast PBH stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 48.020
Low
66.00
Averages
76.00
High
86.00
Current: 48.020
Low
66.00
Averages
76.00
High
86.00
About PBH
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prestige Consumer Healthcare Under Investigation for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Prestige Consumer Healthcare Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- Declining Financial Performance: Prestige reported on May 13, 2026, that its fiscal 2026 revenues decreased by 4.5% year-over-year, with an adjusted gross margin of 55.6% remaining flat compared to the previous year, indicating significant market challenges.
- Stock Price Reaction: Following the earnings report, Prestige's shares fell by 11.35% the next day, reflecting heightened investor concerns about the company's financial health, which could impact future financing and investor confidence.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out for free consultations, highlighting the importance of protecting investor rights and the necessity for legal support in such situations.
See More
Prestige Consumer Healthcare Q4 Earnings Miss Expectations, Shares Plummet
- Earnings Miss: Prestige Consumer Healthcare reported an adjusted EPS of $1.23 for Q4 fiscal 2026, significantly below the expected $1.39, resulting in a sharp decline in share price and highlighting ongoing supply chain issues.
- Revenue Shortfall: The company generated $281.6 million in revenue for the quarter, falling short of analyst forecasts, indicating a severe imbalance between product supply and market demand that could impact future market share.
- Management Promises Unfulfilled: Despite CEO Ron Lombardi's assurances of continued supply chain improvements in Q4, the actual results did not meet expectations, leading to diminished investor confidence and potential legal scrutiny.
- Investigation Launched: Levi & Korsinsky LLP has initiated an investigation into Prestige Consumer Healthcare regarding potential misstatements about supply chain risks prior to the earnings miss, which may expose more investors to losses.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted gross margin for the year was 55.6%, nearly unchanged from 55.8% the previous year, suggesting challenges in cost management that may impact profitability and shareholder returns.
- Sales Miss Expectations: CEO Ron Lombardi noted during the earnings call that Clear Eyes sales fell short due to delayed shipments and production shutdowns, raising concerns about the company's future performance in the market.
- Significant Stock Price Drop: Following the earnings announcement, Prestige's stock price fell by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
Prestige Consumer Healthcare Under Investigation for Securities Violations
- Investigation Launched: The Law Offices of Howard G. Smith announced an investigation into Prestige Consumer Healthcare (NYSE:PBH) regarding potential violations of federal securities laws, indicating significant legal risks that could undermine investor confidence.
- Declining Financial Performance: Prestige Consumer reported a 4.5% year-over-year revenue decline for fiscal 2026, with an adjusted gross margin of 55.6% remaining flat compared to the previous year, highlighting pressures in market competition and challenges to profitability.
- Sales Miss Expectations: CEO Ron Lombardi revealed during the earnings call that Clear Eyes sales fell short of expectations due to shipment delays and production shutdowns, directly leading to a sharp decline in stock price, reflecting operational inefficiencies within the company.
- Severe Stock Price Reaction: On May 14, 2026, Prestige Consumer's shares dropped by $5.88, or 11.35%, closing at $45.93, indicating market concerns over the company's financial health and a drastic deterioration in investor sentiment.
See More
Prestige Consumer Healthcare Reports Q4 2026 Earnings Shortfall Amid Supply Disruptions
- Earnings Decline: Prestige Consumer Healthcare reported Q4 2026 revenue of $281.6 million, a 5% decline year-over-year, primarily due to supply chain issues with Clear Eyes and shipping delays in the Middle East, which negatively impacted the company's competitive position in the eye care market.
- Cash Flow Performance: Despite challenges, the company generated approximately $246 million in free cash flow for fiscal 2026, a slight increase from the previous year, allowing for share repurchases and the acquisition of Pillar5 to enhance long-term eye care output capabilities, demonstrating resilience in adversity.
- Future Outlook: The company forecasts fiscal 2027 revenues between $1.1 billion and $1.12 billion, with organic growth expected at approximately 1% to 3%, and adjusted EPS projected at $4.42 to $4.51, reflecting management's cautious optimism regarding market recovery.
- Risk Factors: Management highlighted heightened uncertainty in the business environment due to supply chain constraints, high inflation, and geopolitical events, particularly the Middle East conflict causing shipping disruptions, which may affect future performance.
See More
Prestige Consumer Healthcare Reports Q4 Misses and FY27 Outlook
- Disappointing Earnings: Prestige Consumer Healthcare reported a Q4 Non-GAAP EPS of $1.23, missing estimates by $0.16, indicating pressure on profitability that may affect investor confidence.
- Revenue Decline: The company's Q4 revenue of $281.6 million represents a 5.0% year-over-year decline, missing expectations by $11.99 million, reflecting challenges from weak market demand and increased competition.
- Future Cash Flow Projections: Projected FY27 GAAP net cash provided by operating activities is $268 million, with $26 million in capital expenditures, leading to a projected Non-GAAP Free Cash Flow of $242 million, indicating a cautious approach to capital spending.
- Adjusted EPS Outlook: The FY27 projected GAAP diluted EPS ranges from $4.31 to $4.40, while the Non-GAAP adjusted diluted EPS is expected to be between $4.42 and $4.51, suggesting that ongoing investments in manufacturing optimization and integration will positively impact profitability.
See More
Prestige Consumer Healthcare Under Investigation for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Prestige Consumer Healthcare Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- Declining Financial Performance: Prestige reported on May 13, 2026, that its fiscal 2026 revenues decreased by 4.5% year-over-year, with an adjusted gross margin of 55.6% remaining flat compared to the previous year, indicating significant market challenges.
- Stock Price Reaction: Following the earnings report, Prestige's shares fell by 11.35% the next day, reflecting heightened investor concerns about the company's financial health, which could impact future financing and investor confidence.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out for free consultations, highlighting the importance of protecting investor rights and the necessity for legal support in such situations.
See More
Prestige Consumer Healthcare Q4 Earnings Miss Expectations, Shares Plummet
- Earnings Miss: Prestige Consumer Healthcare reported an adjusted EPS of $1.23 for Q4 fiscal 2026, significantly below the expected $1.39, resulting in a sharp decline in share price and highlighting ongoing supply chain issues.
- Revenue Shortfall: The company generated $281.6 million in revenue for the quarter, falling short of analyst forecasts, indicating a severe imbalance between product supply and market demand that could impact future market share.
- Management Promises Unfulfilled: Despite CEO Ron Lombardi's assurances of continued supply chain improvements in Q4, the actual results did not meet expectations, leading to diminished investor confidence and potential legal scrutiny.
- Investigation Launched: Levi & Korsinsky LLP has initiated an investigation into Prestige Consumer Healthcare regarding potential misstatements about supply chain risks prior to the earnings miss, which may expose more investors to losses.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted gross margin for the year was 55.6%, nearly unchanged from 55.8% the previous year, suggesting challenges in cost management that may impact profitability and shareholder returns.
- Sales Miss Expectations: CEO Ron Lombardi noted during the earnings call that Clear Eyes sales fell short due to delayed shipments and production shutdowns, raising concerns about the company's future performance in the market.
- Significant Stock Price Drop: Following the earnings announcement, Prestige's stock price fell by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
Prestige Consumer Healthcare Under Investigation for Securities Violations
- Investigation Launched: The Law Offices of Howard G. Smith announced an investigation into Prestige Consumer Healthcare (NYSE:PBH) regarding potential violations of federal securities laws, indicating significant legal risks that could undermine investor confidence.
- Declining Financial Performance: Prestige Consumer reported a 4.5% year-over-year revenue decline for fiscal 2026, with an adjusted gross margin of 55.6% remaining flat compared to the previous year, highlighting pressures in market competition and challenges to profitability.
- Sales Miss Expectations: CEO Ron Lombardi revealed during the earnings call that Clear Eyes sales fell short of expectations due to shipment delays and production shutdowns, directly leading to a sharp decline in stock price, reflecting operational inefficiencies within the company.
- Severe Stock Price Reaction: On May 14, 2026, Prestige Consumer's shares dropped by $5.88, or 11.35%, closing at $45.93, indicating market concerns over the company's financial health and a drastic deterioration in investor sentiment.
See More
Prestige Consumer Healthcare Reports Q4 2026 Earnings Shortfall Amid Supply Disruptions
- Earnings Decline: Prestige Consumer Healthcare reported Q4 2026 revenue of $281.6 million, a 5% decline year-over-year, primarily due to supply chain issues with Clear Eyes and shipping delays in the Middle East, which negatively impacted the company's competitive position in the eye care market.
- Cash Flow Performance: Despite challenges, the company generated approximately $246 million in free cash flow for fiscal 2026, a slight increase from the previous year, allowing for share repurchases and the acquisition of Pillar5 to enhance long-term eye care output capabilities, demonstrating resilience in adversity.
- Future Outlook: The company forecasts fiscal 2027 revenues between $1.1 billion and $1.12 billion, with organic growth expected at approximately 1% to 3%, and adjusted EPS projected at $4.42 to $4.51, reflecting management's cautious optimism regarding market recovery.
- Risk Factors: Management highlighted heightened uncertainty in the business environment due to supply chain constraints, high inflation, and geopolitical events, particularly the Middle East conflict causing shipping disruptions, which may affect future performance.
See More
Prestige Consumer Healthcare Reports Q4 Misses and FY27 Outlook
- Disappointing Earnings: Prestige Consumer Healthcare reported a Q4 Non-GAAP EPS of $1.23, missing estimates by $0.16, indicating pressure on profitability that may affect investor confidence.
- Revenue Decline: The company's Q4 revenue of $281.6 million represents a 5.0% year-over-year decline, missing expectations by $11.99 million, reflecting challenges from weak market demand and increased competition.
- Future Cash Flow Projections: Projected FY27 GAAP net cash provided by operating activities is $268 million, with $26 million in capital expenditures, leading to a projected Non-GAAP Free Cash Flow of $242 million, indicating a cautious approach to capital spending.
- Adjusted EPS Outlook: The FY27 projected GAAP diluted EPS ranges from $4.31 to $4.40, while the Non-GAAP adjusted diluted EPS is expected to be between $4.42 and $4.51, suggesting that ongoing investments in manufacturing optimization and integration will positively impact profitability.
See More
